Application of Deep Eutectic Solvents in the Synthesis of Substituted 2-Mercaptoquinazolin-4(3*H*)-Ones: A Comparison of Selected Green Chemistry Methods

Mario Komar [1], Tatjana Gazivoda Kraljević [2], Igor Jerković [3],* and Maja Molnar [1],*

[1] Faculty of Food Technology Osijek, Josip Juraj Strossmayer University of Osijek, Franje Kuhača 18, HR-31000 Osijek, Croatia; mkomar@ptfos.hr

[2] Department of Organic Chemistry, Faculty of Chemical Engineering and Technology, University of Zagreb, Marulićev Trg 19, HR-10000 Zagreb, Croatia; tgazivod@fkit.hr

[3] Faculty of Chemistry and Technology, University of Split, Ruđera Boškovića 35, HR-21000 Split, Croatia

* Correspondence: igor@ktf-split.hr (I.J.); mmolnar@ptfos.hr (M.M.); Tel.: +385-21-329-434 (I.J.); +385-31-224-342 (M.M.)

Abstract: In this study, deep eutectic solvents (DESs) were used as green and eco-friendly media for the synthesis of substituted 2-mercaptoquinazolin-4(3*H*)-ones from different anthranilic acids and aliphatic or aromatic isothiocyanates. A model reaction on anthranilic acid and phenyl isothiocyanate was performed in 20 choline chloride-based DESs at 80 °C to find the best solvent. Based on the product yield, choline chloride:urea (1:2) DES was found to be the most effective, while DESs acted both as solvents and catalysts. Desired compounds were prepared with moderate to good yields using stirring, microwave-assisted, and ultrasound-assisted synthesis. Significantly, higher yields were obtained with mixing and ultrasonication (16–76%), while microwave-induced synthesis showed lower effectiveness (13–49%). The specific contribution of this research is the use of DESs in combination with the above-mentioned green techniques for the synthesis of a wide range of derivatives. The structures of the synthesized compounds were confirmed by ^{1}H and ^{13}C NMR spectroscopy.

Keywords: deep eutectic solvents; 2-mercaptoquinazolin-4(3*H*)-one; microwave-assisted synthesis; ultrasound-assisted synthesis; green chemistry

1. Introduction

Quinazolinones, as oxygen- and nitrogen-containing fused heterocyclic compounds, are an important scaffold in pharmaceutical and medicinal chemistry showing significant biological activities. They exist in the form of two isomers. The keto functionality may be present on the second, fourth, or both carbon atoms of the quinazoline nucleus (Figure 1) [1].


quinazolin-2(1*H*)-one   quinazolin-4(3*H*)-one   quinazoline-2,4(1*H*,3*H*)-dione

Figure 1. Structure of quinazolinone and quinazolinedione cores [1].

Exceptional biological activities of quinazolinone derivatives have been demonstrated in previous studies investigating their antibacterial [2], antitumor [3], anticonvulsant [4] and anti-inflammatory [5] and enzyme inhibitory activity [6,7]. These compounds have also

been found to act via various targets such as tubulin [8], dihydrofolate reductase [9], histone deacetylase [10], COX-1/COX-2 and 15-LOX [11]. Numerous registered drugs contain quinazolinone core in their structure, such as fenquizone, which is used as a diuretic, raltitrexed, used for selective treatment of different cancers, while balaglitazone is effective anti-diabetic drug and idelalisib as an antineoplastic agent (Figure 2) [12]. An extraordinary biological activity makes them an interesting target for medicinal investigations; therefore, their preparation has been intensified lately [13]. 2-Mercaptoquinazolinones have been a fruitful source in pharmaceutical and medicinal chemistry considering their capability of interacting in hydrogen bonding and π-π stacking with biological targets [14].

Figure 2. Quinazolinone-based registered drugs [12].

The synthesis of quinazolinone derivatives has been the focus of numerous studies for decades, and is therefore well described in the literature. There are many different methods for preparing these extensively studied heterocyclic compounds. Among them, the main synthetic routes use anthranilic acid [15–19], anthranilate [20], isatoic anhydride [21–23], benzoxazinone [24–27] and 2-iodoaniline [28] as convenient precursors. For preparation of 2-mercaptoquinazolinone derivatives, anthranilic acid is the most common starting material. Moussa et al. [11] performed a condensation by heating anthranilic acid and four aromatic isothiocyanates in ethanol for 8 h. The same procedure was performed between 5-iodoanthranilic acid and *p*-chlorophenyl isothiocyanate under reflux for 4 h with 75% yield [29]. Numerous reports have demonstrated the use of triethylamine as a base catalyst in ethanol for condensation of anthranilic acid and appropriate isothiocyanate for 2–4 h [30–32].

Lately, many endeavors have been directed towards much safer, economically acceptable, and environmentally friendly protocols for the preparation of quinazolinones [27,33,34]. Many green procedures use safer solvents and tend to minimize the use of toxic catalysts. Therefore, a novel class of green solvents, deep eutectic solvents (DESs), has found application in green synthetic processes, often serving as both solvents and catalysts. First reported in 2003 [35], DESs are defined as a mixture of two or more components with lower melting point than each individually. Today, DESs are classified into five types based on their general formula [36]. Commonly used, Type III DESs [36], are often formed of hydrogen bond acceptors (HBA), such as quaternary ammonium salts, and hydrogen bond donors (HBD) in different molar ratios. The HBDs employed are often urea and its derivatives, polyols, carbohydrates, and dicarboxylic acids. Their green character is manifested in easy preparation, chemical stability, non-volatility, biodegradability, and non-flammability. These are the

reasons they have been increasingly used in the synthesis of heterocycles, both as catalysts and solvents [37–39]. Hence, a suitable combination of starting components can improve the desired physicochemical properties of DESs for many processes over conventional ones. As green solvents, DESs can be combined with other green chemistry techniques to minimize the adverse environmental effects [40].

In the last two decades, microwave heating has been intensively used in different chemical transformations. Irradiation of polar or less polar molecules due to the absorption of microwaves converted into the heat causes reduced reaction time as well as energy consumption [41]. Besides microwave-assisted synthesis, another efficient green method used to accelerate the organic conversions is an ultrasound-assisted synthesis. The generated high local pressure and temperature inside the bubbles, which collapse, results in remarkable advantages such as enhanced yields, shorter reaction time and better selectivity [42].

Choline chloride-based DESs have been in focus of our investigation for some time, and we found them to be suitable for different chemical processes, both heterocyclic compounds synthesis [17,25,33,43] and extraction [44]. In this regard, the objectives of this research were focused on the investigation on finding an appropriate Type III [36], choline chloride-based deep eutectic (ChCl-based DES) solvent for the synthesis of 3-substituted 2-mercaptoquinazolin-4(3*H*)-one derivatives, as well as on the influence of some reaction parameters such as temperature and reaction time. Furthermore, the use of several suitable green chemistry methods (microwave-assisted synthesis, and ultrasound-assisted synthesis) was also investigated. The DES was recovered and recycled at least several times. Remarkably, this is the first extensive study of the application of 20 choline chloride-based DESs in the synthesis of substituted 2-mercaptoquinazolin-4(3*H*)-ones in a combination with above mentioned green synthetic methods and their comparison.

2. Results and Discussion

Conventionally, 2-mercaptoquinazolin-4(3*H*)-ones have usually been synthesized from anthranilic acid and isothiocyanate using ethanol as a solvent and triethylamine as a base catalyst. Triethylamine is commonly employed in a stoichiometric amount. Novel green techniques in the synthesis of quinazolinones have attracted considerable attention reducing the adverse effects on the environment. Herein, we describe a synthesis of 54 substituted 2-mercaptoquinazolin-4(3*H*)-one derivatives **6a–10k** from anthranilic acids **1–5** and aliphatic and aromatic isothiocyanates (Scheme 1) using DESs by using microwave and ultrasound promoted synthesis. Structures of all synthesized compounds were confirmed by NMR spectroscopy (spectra were shown in Supplementary Material). Chemical shifts in ^{1}H NMR spectra indicate that all compounds are in thiol form, where the characteristic shift for thiol proton is usually found around 12 ppm. All other characteristic chemical shifts indicate the presence of quinoline core, as well as aromatic and aliphatic substituents.

1: R^1 = H
2: R^1 = 5-I
3: R^1 = 5-Br
4: R^1 = 4-Cl
5: R^1 = 3,5-(Cl)$_2$

6a–k
7a–k
8a–k
9a–k
10a–k

Scheme 1. Synthesis of substituted 2-mercaptoquinazolin-4(3*H*)-ones by green methods.

The first step of this investigation began with optimization of the reaction conditions using anthranilic acid **1** and phenyl isothiocyanate as model substrates. As our previous

results [33] indicated that products could be easily synthesized in ChCl:urea (1:2) DES, we investigated the influence of reaction temperature (40 °C, 60 °C, and 80 °C) and time (30 min, 1 h and 2 h) in this DES. The consumption of the reactants was monitored with thin layer chromatography (TLC). As expected, the highest temperature of 80 °C after 1 h and 2 h provided the best product yields equally (63%), while 40 °C and 60 °C after 2 h provided 14%, and 29%, respectively. Therefore, we used the temperature of 80 °C for all reactions performed in the remaining 19 DESs (Table 1). A temperature of 80 °C was also suitable for the DESs such as ChCl:fructose (2:1), ChCl:glucose (2:1), ChCl:citric acid (1:1), ChCl:tartaric acid (1:1), which are too viscous at lower temperatures, but yet not degraded at this temperature.

Table 1. 2-Mercapto-3-phenylquinazolin-4(3*H*)-one yields obtained in different choline chloride-based DESs at 80 °C.

Entry	DES	Molar Ratio	Yield ** (%)
1	ChCl:Urea	1:2	63
2	ChCl:*N*-methylurea	1:3	59
3	ChCl:1,3-Dimethylurea	1:2	24
4	ChCl:Thiourea	1:2	20
5	ChCl:Acetamide	1:2	33
6	ChCl:Butane-1,4-diol	1:2	47
7	ChCl:Ethane-1,2-diol	1:2	24
8	ChCl:Glycerol	1:2	21
9	ChCl:Xylitol	1:1	14
10	ChCl:Sorbitol	1:1	10
11	ChCl:Glucose	2:1	*
12	ChCl:Fructose	2:1	*
13	ChCl:Citric acid	1:1	*
14	ChCl:Tartaric acid	1:1	*
15	ChCl:Oxalic acid	1:1	*
16	ChCl:Levulinic acid	1:2	*
17	ChCl:Lactic acid	1:2	*
18	ChCl:Malic acid	1:1	*
19	ChCl:Malonic acid	1:1	*
20	ChCl:Maleic acid	1:1	*

* The product was not obtained. ** The yields were calculated based on the anthranilic acid for the product after precipitation.

The used molar ratio of the components was chosen upon literature data described before [35,37,45,46]. The product yields are shown in Table 1.

Results in Table 1 indicate that the best yield was obtained in choline chloride:urea (1:2) DES at 80 °C This yield was lower than the one obtained in our previous work [33], but this is probably due to the lower reaction temperature. As already mentioned, the temperature of 80 °C was chosen as suitable for the sugar-based DESs, since they decompose at higher temperatures. As conventional synthesis of 2-mercaptoquinazolin-4(3*H*)-ones is usually base catalyzed (often by triethylamine) it is not surprising that choline chloride:urea (1:2), a basic DES [47], gave the best yields. It can be concluded that the formation of quinazolinones in DESs is pH-dependent, with higher yields in basic DESs.

Therefore, all desired products **6a–10k** (Scheme 1) were synthesized in ChCl:urea (1:2) DES by simple stirring of the reaction mixture at 80 °C (Table 2).

In general, the compounds with aliphatic groups at C-3 of quinazolinone core were obtained in lower yields, probably due to their higher solubility in water during the isolation.

Table 2. A comparison of the substituted 2-mercaptoquinazolin-4(3*H*)-ones yields[1] obtained with selected green methods with literature yields.

Compounds	R[1]	Ar/R[2]	$Y_{stirring}$ (%) [2]	Y_{MW} (%) [3]	Y_{US} [4] (%)	$Y_{Lit.}$ (%)	M_p (°C)
6a	H	Me	42	39	17	46 [48]; 68 [33]; 60 [49]	264–265
6b	H	Et	40	18	36	72 [33]; 95 [50]	255
6c	H	Allyl	24	15	21	35 [33]	206–208
6d	H	Ph	63	22	34	35 [48]; 90 [33]; 92 [50]; 73 (82) [51]; 61 [49]; 75 (60) [52]	304–305
6e	H	Bn	62	41	64	50 [48]; 83 [53]	248–250
6f	H	4-MePh	27	47	38	94 [50]; 79 (78) [51]; 88 [54], 75 (62) [52]	312–313
6g	H	4-FPh	48	32	25	88 [3]; 88 [54]	336–337
6h	H	4-ClPh	55	49	41	75 [33]; 89 [50]; 94 [51]	331–332
6i	H	4-BrPh	66	24	58	84 [55]; 70 [52]	330–331
6j	H	3-OMePh	64	21	57	91 [54]; 65 (50) [52]	285
6k	H	3-ClPh	41	12	25	86 [54]	300–301
7a	6-I	Me	31	20	40	73 [33]	307–308
7b	6-I	Et	25	14	18	10 [33]	290–292
7c	6-I	Allyl	22	13	21	20 [33]	234–235
7d	6-I	Ph	32	16	22	91 [33]; 70 [52]	350–352
7e	6-I	Bn	45	10	28		352
7f	6-I	4-MePh	49	29	47		350–351
7g	6-I	4-FPh	43	22	18		349–350
7h	6-I	4-ClPh	39	31	38	75 [29]	337–339
7i	6-I	4-BrPh	49	30	51		355–357
7j	6-I	3-OMePh	53	25	58		314–315
7k	6-I	3-ClPh	50	25	44		313–315
8a	6-Br	Me	21	14	23	64 [49]	280–281
8b	6-Br	Et	25	13	17		243–244
8c	6-Br	Allyl	40	14	40		242–243
8d	6-Br	Ph	36	13	19	63 [49]; 75 [52]	351–353
8e	6-Br	Bn	58	27	60		244
8f	6-Br	4-MePh	76	31	41	60 [56]	341–342
8g	6-Br	4-FPh	57	19	28		354–355
8h	6-Br	4-ClPh	62	27	48		344–346
8i	6-Br	4-BrPh	65	33	56		349–350

Table 2. *Cont.*

Compounds	R [1]	Ar/R [2]	$Y_{stirring}$ (%) [2]	Y_{MW} (%) [3]	Y_{US} [4] (%)	$Y_{Lit.}$ (%)	M_p (°C)
8j	6-Br	3-OMePh	49	28	30		312–313
8k	6-Br	3-ClPh	57	18	33		305–307
9a	7-Cl	Me	58	19	18		327–328
9b	7-Cl	Et	22	15	21		265
9c	7-Cl	Allyl	47	13	26		248–249
9d	7-Cl	Ph	67	19	36	71 (90) [51]	313–314
9e	7-Cl	Bn	26	17	34		270–272
9f	7-Cl	4-MePh	42	13	24	73 [51]	307–309
9g	7-Cl	4-FPh	34	18	18		314–315
9h	7-Cl	4-ClPh	50	14	27	76 [53]	302–303
9i	7-Cl	4-BrPh	50	16	38		320–322
9j	7-Cl	3-OMePh	40	25	44		256–257
9k	7-Cl	3-ClPh	39	19	54		248–249
10a	6,8-(Cl)$_2$	Me	36	15	41		246–247
10b	6,8-(Cl)$_2$	Et	19	119	15		184
10c	6,8-(Cl)$_2$	Allyl	21	23	30		179
10d	6,8-(Cl)$_2$	Ph	20	18	19	65 [52]	283–285
10e	6,8-(Cl)$_2$	Bn	51	14	27		206–208
10f	6,8-(Cl)$_2$	4-MePh	25	27	40	70 [52]	244
10g	6,8-(Cl)$_2$	4-FPh	33	22	24		268–269
10h	6,8-(Cl)$_2$	4-ClPh	34	30	30		259–260
10i	6,8-(Cl)$_2$	4-BrPh	60	37	48		280–282
10j	6,8-(Cl)$_2$	3-OMePh	33	14	24		219–220
10k	6,8-(Cl)$_2$	3-ClPh	38	24	43		214–216

[1] The yields were calculated based on the anthranilic acid for the product after precipitation; [2] ChCl:urea (1:2), 80 °C, 1 h; [3] ChCl:urea (1:2), 1800 W, 80 °C, 1 h; [4] ChCl:urea (1:2), 50 W, 80 °C, 1 h.

To explore the efficiency of current procedure, we performed the microwave and ultrasound induced synthesis of all compounds in the same solvent, as well. Microwave-induced synthesis of the model reaction was performed at 80 °C and 1800 W for 15 min, 30 min and 60 min. The desired product **6d** was obtained in traces after 15 min and 30 min, and only in 22% after 60 min. In this manner, the synthesis of all other derivatives was performed at 80 °C and 1800 W for 60 min (Table 2).

The ultrasound induced synthesis of the model reaction was performed at 50 W and 80 °C for 15 min, 30 min and 60 min affording the desired product **6d** in 14%, 15%, and 34%. Therefore, all the reactions were performed for 60 min at 50 W and 80 °C, and the results are shown in Table 2.

Besides its desirable character, the synthesis in DES is characterized by the simplicity of the postsynthetic procedures, which include the addition of water into reaction mixture followed by the product precipitation. The products are pure and only several derivatives **6c**, **6j**, **7b**, **9b**, **9c**, **9i** and **10a–10k** were recrystallized from ethanol. Although some other authors have obtained higher yields of some derivatives (Table 2), their synthetic procedures often included long reaction times [48,52], reflux conditions [3,29,50–53,55,57], use of different catalysts, and extensive postsynthetic procedures using different harmful organic solvents [29,50,53–55].

The recyclability of choline chloride:urea (1:2) DES in this investigation was examined using 5-bromoanthranilic acid **3** and *p*-tolyl isothiocyanate under optimal conditions (Table 3). After the consumption of 5-bromoanthranilic acid, the reaction mixture was cooled and diluted with water. The desired product was filtered off and washed with water. The water was removed under vacuum and DES was recovered and re-used for the same reaction. The reusability proceeded four times with no significant loss of activity.

Table 3. Recyclability of DES for the synthesis of **8f**.

Solvent	Yield of 8f (%)
ChCl:Urea	76
1st recycle	72
2nd recycle	77
3rd recycle	80
4th recycle	77

According to the conducted experiments and reported data [31], a plausible mechanism for the condensation of anthranilic acids **1–5** and isothiocyanates is presented in Scheme 2. The first step includes a nucleophilic attack of a nitrogen atom to an electron-deficient carbon atom from isothiocyanate in the presence of choline chloride:urea (1:2) DES (marked green on Scheme 2). Subsequently, the intermediate undergoes cyclization and the required quinazolinone is formed through dehydration.

Scheme 2. A plausible mechanism for the synthesis of substituted 2-mercaptoquinazolin-4(3*H*)-ones.

The greenness of this process is presented by calculation of the Sheldon's *E-factor*:

$$E - factor = \frac{kg \ (waste)}{kg \ (product)} = \frac{0.00013 \ kg}{0.000265 \ kg} = 0.49 \tag{1}$$

3. Experimental Section

3.1. Materials and Methods

All chemicals and solvents were purchased from commercial suppliers and used without purification. Choline chloride (99%), *N*-methylurea (97%), 1,3-dimethylurea (98%), thiourea (99+%), acetamide (99%), butane-1,4-diol (99+%), xylitol (99+%), oxalic acid (98%, anhydrous), levulinic acid (98+%), malic acid (99+%), malonic acid (99%), anthranilic acid (98+%), 5-iodoanthranilic acid (98%), 5-bromoanthranilic acid (97%), 4-chloroanthranilic acid (98%), methyl isothiocyanate (97%), ethyl isothiocyanate (96%), allyl isothiocyanate (94% stabilized with 0.01% α-tocopherol), phenyl isothiocyanate (98%), benzyl isothiocyanate (98%) were purchased from Acros Organics (Geel, Belgium). 4-Methylphenyl isothiocyanate (97%), 3,5-dichloroanthranilic acid (97%) were purchased from Alfa Aesar (Lancashire, UK). 3-Bromophenyl isothiocyanate (97%), 3-methoxyphenyl isothiocyanate (987+%) were purchased from Maybridge (Maybridge Chemical Company Ltd., Altrincham, UK). Urea (p.a.), glycerol (redistilled, p.a.), D(+)-glucose (p.a.), citric acid (p.a.) were purchased from Gram Mol. Ethane-1,2-diol (p.a.) was purchased from Carlo Erba (Carlo Erba Reagents GmbH, Emmendingen, Germany). Sorbitol (lab. reag. grade), D(+)-fructose (lab. reag. grade), L(+)-tartaric acid (lab. reag. grade) were purchased from Fischer Scientific (Fisher Scientific UK Ltd., Loughborough, UK). 4-Fluorophenyl isothiocyanate (98%), 4-chlorophenyl isothiocyanate (99%), 3-chlorophenyl isothiocyanate (98%), maleic acid (reag. plus. ≥99% HPLC) was purchased from Sigma Aldrich (Sigma Aldrich Chemie

GmbH, München, Germany). Lactic acid (min. 88%, p.a.) was purchased from T.T.T. (T.T.T. d.o.o., Sveta Nedelja, Croatia). Melting points (uncorrected) were determined in open capillaries on Electrothermal melting point apparatus (Electrothermal Engineering Ltd., Rochford, UK). For monitoring the progress of a reaction, thin layer chromatography (TLC) was performed on pre-coated Merck (Darmstadt, Germany) silica gel 60F-254 plates using benzene:acetic acid:acetone (8:1:1, *v/v*) as solvent system and the spots were detected under UV light (254 nm). ^{1}H and ^{13}C NMR spetra were recorded on a Bruker 600 MHz spectrometer (Bruker Biospin, Rheinstetten, Germany) at 298 K in dimethylsulfoxide (DMSO-d_6). The synthesis by mixing and heating was performed on a magnetic stirrer (IKA RH basic 2, Staufen, Germany). Microwave-assisted synthesis was performed using Milestone flexi-WAVE reactor (Milestones Srl, Milan, Italy) with the power at 1800 W. Ultrasound-assisted synthesis was performed in temperature controlled ultrasonic bath (Elma P70 H, Singen, Germany) with frequency at 37 Hz and the power at 50 W.

3.2. Preparation of DESs

DESs were prepared by mixing choline chloride with appropriate amides, carbohydrates, alcohols and carboxylic acids in a different molar ratio, as listed in Table 1. The mixtures were heated at 80 °C with continuous stirring until a clear liquid was obtained. The prepared DESs was used as such as described in Sections 3.3–3.5.

3.3. Synthesis of Substituted 2-Mercaptoquinazolin-4(3H)-Ones by Mixing and Heating Preparation of DESs

Anthranilic acid **1–5** (1 mmol) and corresponding isothiocyanate (1.2 mmol) were added to 10 mL of DES and stirred at 80 °C for 1 h. Upon completion of the reaction, water was added, and the precipitated product was filtered off. When necessary, a recrystallization was performed using ethanol.

3.4. Microwave-Assisted Synthesis of Substituted 2-Mercaptoquinazolin-4(3H)-ones

Anthranilic acid **1–5** (1 mmol) and corresponding isothiocyanate (1.2 mmol) in 10 mL of DES were stirred under microwave irradiation (1800 W) at 80 °C for 1 h. Upon completion of the reaction, water was added, and the precipitated product was filtered.

3.5. Ultrasound-Assisted Synthesis of Substituted 2-Mercaptoquinazolin-4(3H)-ones

Anthranilic acid **1–5** (1 mmol) and corresponding isothiocyanate (1.2 mmol) in 10 mL of DES were subjected to ultrasonic irradiation at 50 W and 80 °C for 1 h. Upon completion of the reaction, water was added, and the precipitated product was filtered.

3.6. Recycling of DES

5-Bromoanthranilic acid **3** (216 mg; 1 mmol) and *p*-tolyl isothiocyanate (165 μL; 1.2 mmol) in 10 mL of DES were mixed and heated on magnetic stirrer at 80 °C for 1 h. Upon addition of the water, a crude product was precipitated, and the water was evaporated. The procedure was repeated four times. The Sheldon's *E-factor* was calculated according to the following formula as described in our previous work [43]:

$$E - factor = \frac{kg\ (waste)}{kg\ (product)} \tag{2}$$

3.7. Characterization of Compounds

Spectra Are Shown in Supplementary Materials.

3.7.1. 2-Mercapto-3-methylquinazolin-4(3H)-one (**6a**)

Pale yellow powder; mp = 264–265 °C (262–264 °C [48]); R_f = 0.79; ^{1}H NMR (DMSO-d_6, 400 MHz) δ 12.9 (1H, s, –SH), 7.93 (1H, d, *J* = 7.54 Hz, arom.), 7.73 (1H, m, arom.), 7.37 (1H,

d, *J* = 7.91 Hz, arom.), 7.32 (1H, t, *J* = 7.54 Hz, arom.), 3.64 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.3, 159.6, 138.9, 135.3, 127.2, 124.3, 115.5, 33.2.

3.7.2. 3-Ethyl-2-mercaptoquinazolin-4(3*H*)-one (**6b**)

Pale yellow powder; mp = 255 °C (246–248 °C [50]); R_f = 0.82; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.9 (1H, s, -SH), 7.93–7.96 (1H, m, arom.), 7.69–7.75 (1H, m, arom.), 7.36 (1H, d, *J* = 8.29 Hz, arom.), 7.29–7.34 (1H, m, arom.), 4.41–4.48 (2H, q, *J* = 7.16 Hz, -CH$_2$-), 1.20–1.25 (3H, t, *J* = 6.97 Hz, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 174.7, 158.9, 138.9, 135.3, 127.2, 124.4, 115.5, 99.5, 11.9.

3.7.3. 3-Allyl-2-mercaptoquinazolin-4(3*H*)-one (**6c**)

Pale yellow powder; mp = 206–208 °C (206 °C [33]); R_f = 0.77; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.9 (1H, s, -SH), 7.94–7.96 (1H, d, *J* = 7.54 Hz, arom.), 7.71–7.76 (1H, m, arom.), 7.36–7.41 (1H, d, *J* = 8.29 Hz, arom.), 7.30–7.33 (1H, t, *J* = 7.54, 7.54 Hz, arom.), 5.87–5.96 (1H, m, -CH-), 5.17 (2H, d, *J* = 6.97 Hz, -CH=), 5.04 (2H, d, *J* = 4.90 Hz, =CH$_2$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.0, 158.9, 139.1, 135.5, 131.8, 127.3, 124.5, 117.1, 115.6, 99.5, 47.6.

3.7.4. 2-Mercapto-3-phenylquinazolin-4(3*H*)-one (**6d**)

White powder; mp = 304–305 °C (300–302 °C [48]); R_f = 0.80; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.0 (1H, s, -SH), 7.97 (1H, dd, *J* = 7.91, 1.13 Hz, arom.), 7.76–7.81 (1H, t, arom.), 7.29–7.51 (7H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.0, 159.8, 139.6, 139.3, 135.6, 128.9, 128.1, 127.4, 124.3, 115.7.

3.7.5. 3-Benzyl-2-mercaptoquinazolin-4(3*H*)-one (**6e**)

White powder; mp = 248–250 °C (231–233 °C [48]); R_f = 0.77; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.1 (1H, s, -SH), 7.95–7.97 (1H, m, arom.), 7.73–7.79 (1H, m, arom.), 7.42–7.44 (1H, d, *J* = 8.29 Hz, arom.), 7.23–7.38 (7H, m, arom.), 5.67 (2H, s, -CH$_2$-). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.5, 159.4, 139.1, 136.6, 128.2, 127.1, 124.6, 115.7, 48.7.

3.7.6. 2-Mercapto-3-(p-tolyl)quinazolin-4(3H)-one (6f)

White powder; mp = 312–313 °C (318–320 °C [50]); R_f = 0.76; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.0 (1H, s, -SH), 7.95 (1H, d, *J* = 7.54 Hz, arom.), 7.75–7.78 (1H, m, arom.), 7.45 (1H, d, *J* = 7.91 Hz, arom.), 7.26–7.37 (3H, m, arom.), 7.13–7.15 (2H, d, *J* = 7.91 Hz, arom.), 2.37 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.2, 159.8, 139.5, 137.3, 135.5, 130.3, 129.4, 128.6, 127.4, 125.7, 124.3, 116.1, 115.7, 20.8.

3.7.7. 3-(4-Fluorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**6g**)

White powder; mp = 336–337 °C (>300 °C [3]); R_f = 0.76; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.1 (1H, s, -SH), 7.95 (1H, m, arom.), 7.76–7.81 (1H, m, arom.), 7.44–7.47 (1H, d, *J* = 7.91 Hz, arom.), 7.27–7.38 (5H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.1, 163.1, 159.9, 139.5, 135.6, 131.0, 127.4, 124.3, 115.7, 99.5.

3.7.8. 3-(4-Chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**6h**)

White powder; mp = 331–332 °C (>300 °C [51]); R_f = 0.75; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.1 (1H, s, -SH), 7.95 (1H, d, *J* = 7.91 Hz, arom.), 7.76–7.82 (1H, m, arom.), 7.53–7.56 (2H, m, arom.), 7.44–7.47 (1H, m, arom.), 7.33–7.35 (3H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 159.8, 139.6, 138.2, 135.6, 132.7, 131.0, 129.0, 127.4, 124.4, 116.2, 115.7, 99.5.

3.7.9. 3-(4-Bromophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**6i**)

White powder; mp = 330–331 °C (300–301 °C [55]); R_f = 0.78; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.1 (1H, s, -SH), 7.95 (1H, dd, *J* = 7.91, 0.75 Hz, arom.), 7.76–7.79 (1H, m, arom.), 7.57–7.70 (2H, m, arom.), 7.44–7.47 (1H, d, *J* = 8.29 Hz, arom.), 7.33–7.35 (1H, m, arom.),

7.27–7.30 (2H, d, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 159.8, 139.6, 138.7, 135.6, 132.1, 131.2, 127.4, 124.4, 121.3, 116.2, 115.7.

3.7.10. 2-Mercapto-3-(3-methoxyphenyl)quinazolin-4(3*H*)-one (**6j**)

White powder; mp = 285 °C (248–249 °C [54]); R_f = 0.75; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.0 (1H, s, -SH), 7.95 (1H, m, arom.), 7.78 (1H, m, arom.), 7.38–7.46 (3H, m, arom.), 7.0 (1H, dd, *J* = 7.91, 2.26 Hz, arom.), 6.84–6.91 (2H, m, arom.), 3.76 (3H, s, -OCH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 159.8, 140.3, 139.6, 135.5, 129.4, 127.4, 124.4, 121.2, 116.2, 115.6, 114.9, 113.6, 99.5, 55.2.

3.7.11. 3-(3-Chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**6k**)

White powder; mp = 300–301 °C (231–233 °C [54]); R_f = 0.74; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.1 (1H, s, -SH), 7.95 (1H, m, arom.), 7.77 (1H, m, arom.), 7.28–7.52 (6H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 159.7, 140.6, 139.6, 135.6, 132.9, 130.6, 129.4, 129.2, 128.2, 128.1, 127.4, 124.4, 116.2, 115.7.

3.7.12. 6-Iodo-2-mercapto-3-methylquinazolin-4(3*H*)-one (**7a**)

Pale yellow powder; mp = 307–308 °C (271 °C [33]); R_f = 0.80; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.99 (1H, s, -SH), 8.16 (1H, s, arom.), 7.99 (1H, dd, *J* = 8.67, 1.88 Hz, arom.), 7.15–7.18 (1H, d, *J* = 8.29, arom.), 3.63 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.3, 158.3, 143.2, 138.4, 135.2, 117.9, 117.2, 87.8, 33.3.

3.7.13. 3-Ethyl-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7b**)

White powder; mp = 290–292 °C (281 °C [33]); R_f = 0.85; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.96 (1H, s, -SH), 8.17 (1H, s, arom.), 8.00 (1H, d, *J* = 8.67 Hz, arom.), 7.15–7.18 (1H, d, *J* = 8.67 Hz, arom.), 4.38–4.45 (2H, q, *J* = 6.78 Hz, -CH$_2$-), 1.19–1.23 (1H, t, *J* = 6.78 Hz, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 174.7, 157.7, 143.4, 138.4, 135.2, 117.9, 117.5, 87.9, 41.4, 11.8.

3.7.14. 3-Allyl-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7c**)

Pale yellow powder; mp = 234–235 °C (219 °C [33]); R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.02 (1H, s, -SH), 8.17 (1H, d, *J* = 2.26 Hz, arom.), 8.01–8.05 (1H, dd, *J* = 8.67, 1.88 Hz, arom.), 7.17–7.20 (1H, d, *J* = 8.67 Hz, arom.), 5.89 (1H, m, -CH=), 5.12–5.18 (2H, m, -CH$_2$-), 5.00–5.02 (2H, d, *J* = 5.27 Hz, =CH$_2$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 174.9, 157.8, 143.6, 138.5, 135.2, 131.5, 117.9, 117.3, 87.9, 47.8.

3.7.15. 6-Iodo-2-mercapto-3-phenylquinazolin-4(3*H*)-one (**7d**)

White powder; mp = 350–352 °C (>300 °C [33]); R_f = 0.86; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.01 (1H, s, -SH), 8.17 (1H, d, *J* = 1.47 Hz, arom.), 8.06–8.08 (1H, dd, *J* = 8.44, 1.83 Hz, arom.), 7.46–7.49 (2H, m, arom.), 7.41 (1H, m, arom.), 7.24–7.27 (3H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.0, 158.6, 143.6, 139.1, 135.2, 128.9, 128.2, 118.2, 117.9, 87.7.

3.7.16. 3-Benzyl-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7e**)

White powder; mp = 352 °C; R_f = 0.89; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.12 (1H, s, -SH), 8.18 (1H, d, *J* = 1.88 Hz, arom.), 8.03–8.07 (1H, dd, *J* = 8.48, 2.07 Hz, arom.), 7.20–7.33 (6H, m, arom.), 5.63 (2H, s, -CH$_2$-). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.5, 158.2, 143.6, 138.5, 136.3, 135.2, 128.2, 127.0, 117.9, 117.4, 88.1, 48.8.

3.7.17. 6-Iodo-2-mercapto-3-(p-*t*olyl)quinazolin-4(3*H*)-one (**7f**)

White powder; mp = 350–351 °C; R_f = 0.87; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.06 (1H, s, -SH), 8.17 (1H, d, *J* = 1.47 Hz, arom.), 8.06–8.08 (1H, dd, *J* = 8.80, 2.20 Hz, arom.), 7.27 (2H, d, *J* = 1.47 Hz, arom.), 7.24 (1H, d, *J* = 8.80 Hz, arom.), 7.12–7.13 (2H, d, *J* = 8.07 Hz, arom.), 2.37 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.1, 158.6, 143.6, 138.9, 137.5, 136.5, 135.2, 129.4, 128.5, 118.2, 117.9, 87.6, 20.8.

3.7.18. 3-(4-Fluorophenyl)-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7g**)

Pale yellow powder; mp = 349–350 °C; R_f = 0.77; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.12 (1H, s, -SH), 8.17 (1H, d, *J* = 1.88 Hz, arom.), 8.06–8.09 (1H, dd, *J* = 8.48, 2.07 Hz, arom.), 7.31–7.33 (3H, m, arom.), 7.23–7.26 (1H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.1, 163.2, 159.9, 158.6, 143.8, 138.9, 135.3, 131.1, 118.2, 117.9, 115.9, 115.7, 87.7, 20.8.

3.7.19. 3-(4-Chlorophenyl)-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7h**)

Pale yellow powder; mp = 337–339 °C (320–321 °C [29]); R_f = 0.84; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.14 (1H, s, -SH), 8.17 (1H, d, *J* = 1.88 Hz, arom.), 8.06–8.09 (1H, dd, *J* = 8.67, 1.88 Hz, arom.), 7.53–7.56 (2H, d, *J* = 8.67 Hz, arom.), 7.31–7.34 (2H, d, *J* = 8.67 Hz, arom.), 7.23–7.26 (1H, d, *J* = 8.29 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 158.5, 143.6, 138.9, 138.0, 135.2, 132.8, 130.9, 129.0, 118.2, 117.9, 87.7.

3.7.20. 3-(4-Bromophenyl)-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7i**)

White powder; mp = 355–357 °C; R_f = 0.87; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.14 (1H, s, -SH), 8.17 (1H, d, *J* = 1.88 Hz, arom.), 8.07–8.10 (1H, dd, *J* = 8.48, 2.07 Hz, arom.), 7.67–7.70 (2H, m, arom.), 7.22–7.27 (3H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.5, 143.6, 138.9, 138.5, 135.2, 132.1, 131.3, 121.4, 118.2, 117.9, 99.5, 87.7.

3.7.21. 6-Iodo-2-mercapto-3-(3-methoxyphenyl)quinazolin-4(3*H*)-one (**7j**)

White powder; mp = 314 °C; R_f = 0.71; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.08 (1H, s, -SH), 8.17 (1H, d, *J* = 1.88 Hz, arom.), 8.06–8.09 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.36–7.41 (1H, m, arom.), 7.22–7.25 (1H, d, *J* = 8.67 Hz, arom.), 7.00 (1H, dd, *J* = 8.10, 2.07 Hz, arom.), 6.84–6.90 (1H, t, *J* = 2.07 Hz, arom.), 6.85 (1H, d, *J* = 7.54 Hz, arom.), 3.76 (3H, s, -OCH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 159.8, 158.4, 143.6, 140.1, 138.9, 135.2, 129.6, 121.1, 117.9, 114.8, 113.7, 87.7, 55.3.

3.7.22. 3-(3-Chlorophenyl)-6-iodo-2-mercaptoquinazolin-4(3*H*)-one (**7k**)

White powder; mp = 313–314 °C; R_f = 0.83; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.15 (1H, s, -SH), 8.18 (1H, d, *J* = 1.88 Hz, arom.), 8.07–8.10 (1H, dd, *J* = 8.67, 1.88 Hz, arom.), 7.46–7.52 (3H, m, arom.), 7.23–7.31 (2H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.5, 143.7, 140.4, 139.1, 135.2, 132.9, 130.5, 129.12, 128.4, 128.0, 118.2, 117.9, 87.8.

3.7.23. 6-Bromo-2-mercapto-3-methylquinazolin-4(3*H*)-one (**8a**)

White powder; mp = 280–281 °C (270 °C [49]); R_f = 0.81; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.02 (1H, s, -SH), 7.99 (1H, d, *J* = 1.88 Hz, arom.), 7.89 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.31–7.33 (1H, d, *J* = 8.67 Hz, arom.), 3.63 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.3, 158.5, 138.1, 137.9, 129.1, 118.1, 116.9, 115.9, 33.3.

3.7.24. 6-Bromo-3-ethyl-2-mercaptoquinazolin-4(3*H*)-one (**8b**)

White powder; mp = 243–244 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.99 (1H, s, -SH), 7.99 (1H, d, *J* = 1.88 Hz, arom.), 7.86–7.89 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.29–7.33 (1H, d, *J* = 8.67 Hz, arom.), 4.38–4.45 (2H, q, *J* = 6.78 Hz, -CH$_2$-), 1.19–1.24 (3H, t, *J* = 6.97, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.3, 158.5, 138.1, 137.9, 129.1, 118.1, 116.9, 115.9, 33.3.

3.7.25. 3-Allyl-6-bromo-2-mercaptoquinazolin-4(3*H*)-one (**8c**)

White powder; mp = 242–243 °C; R_f = 0.85; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.06 (1H, s, -SH), 8.02 (1H, d, *J* = 2.26 Hz, arom.), 7.89–7.93 (1H, dd, *J* = 8.85, 2.07 Hz, arom.), 7.32–7.35 (1H, d, *J* = 8.67 Hz, arom.), 5.90 (1H, qd, *J* = 10.99, 5.09 Hz, -CH=), 5.16–5.19 (2H, m, *J* = 6.97 Hz, -CH$_2$-), 5.01 (2H, d, *J* = 5.27, =CH$_2$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.3, 158.5, 138.1, 137.9, 129.1, 118.1, 116.9, 115.9, 33.3.

3.7.26. 6-Bromo-2-mercapto-3-phenylquinazolin-4(3*H*)-one (**8d**)

White powder; mp = 351–353 °C (322 °C [49]); R_f = 0.76; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.14 (1H, s, -SH), 8.01 (1H, d, *J* = 2.26 Hz, arom.), 7.93–7.97 (1H, dd, *J* = 9.04, 2.26 Hz, arom.), 7.38–7.51 (4H, m, arom.), 7.26–7.29 (2H, d, *J* = 7.16 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.1, 158.7, 139.1, 138.2, 129.3, 128.9, 128.8, 128.2, 118.1, 115.9.

3.7.27. 3-Benzyl-6-bromo-2-mercaptoquinazolin-4(3*H*)-one (**8e**)

White powder; mp = 244 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.16 (1H, s, -SH), 8.01 (1H, d, *J* = 1.88 Hz, arom.), 7.90–7.94 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.22–7.38 (6H, m, arom.), 5.65 (2H, d, *J* = 7.16 Hz, -CH$_2$-). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.5, 158.4, 138.2, 136.3, 129.39, 128.2, 127.1, 126.9, 118.1, 117.2, 116.2, 48.8.

3.7.28. 6-Bromo-2-mercapto-3-(*p*-tolyl)quinazolin-4(3*H*)-one (**8f**)

White powder; mp = 341–342 °C (> 300 °C [56]); R_f = 0.82; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.10 (1H, s, -SH), 8.01 (1H, d, *J* = 2.20 Hz, arom.), 7.93–7.95 (1H, dd, *J* = 8.80, 2.20 Hz, arom.), 7.37–7.39 (1H, d, *J* = 8.80 Hz, arom.), 7.26–7.28 (1H, d, *J* = 8.07 Hz, arom.), 7.12–7.14 (2H, m, arom.), 2.37 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.2, 158.7, 138.7, 138.1, 137.5, 136.5, 129.4, 128.5, 118.1, 117.9, 115.8, 20.8.

3.7.29. 6-Bromo-3-(4-fluorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**8g**)

White powder; mp = 354–355 °C; R_f = 0.81; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.15 (1H, s, -SH), 8.01 (1H, d, *J* = 2.26 Hz, arom.), 7.94–7.97 (1H, dd, *J* = 8.85, 2.45 Hz, arom.), 7.31–7.41 (5H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.1, 163.2, 159.9, 158.8, 138.7, 138.3, 135.3, 131.3, 130.8, 129.3, 118.1, 115.9, 115.6.

3.7.30. 6-Bromo-3-(4-chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**8h**)

White powder; mp = 344–345 °C; R_f = 0.81; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.175 (1H, s, -SH), 8.01 (1H, d, *J* = 2.20 Hz, arom.), 7.94–7.96 (1H, dd, *J* = 8.80, 2.40 Hz, arom.), 7.54–7.56 (2H, m, arom.), 7.38–7.40 (1H, m, arom.), 7.32–7.34 (2H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.7, 138.7, 138.2, 137.9, 132.8, 130.9, 129.3, 129.0, 118.1, 118.0, 115.9.

3.7.31. 6-Bromo-3-(4-bromophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**8i**)

White powder; mp = 349–350 °C; R_f = 0.77; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.18 (1H, s, -SH), 8.02 (1H, d, *J* = 2.26 Hz, arom.), 7.94–7.98 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.67–7.70 (2H, m, arom.), 7.41 (1H, d, *J* = 9.04 Hz, arom.), 7.26–7.29 (2H, d, *J* = 8.29 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.7, 138.7, 138.2, 137.9, 132.8, 130.9, 129.3, 129.0, 118.1, 118.0, 115.9.

3.7.32. 6-Bromo-2-mercapto-3-(3-methoxyphenyl)quinazolin-4(3*H*)-one (**8j**)

White powder; mp = 312–313 °C; R_f = 0.73; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.11 (1H, s, -SH), 8.00 (1H, d, *J* = 2.20 Hz, arom.), 7.93–7.95 (1H, dd, *J* = 8.80, 2.20 Hz, arom.), 7.37–7.40 (2H, m, arom.), 6.99 (1H, dd, *J* = 8.07, 2.20 Hz, arom.), 6.90 (1H, t, *J* = 2.20, 2.20 Hz, arom.), 6.84–6.86 (1H, m, arom.), 3.76 (3H, s, -OCH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 159.8, 158.6, 140.1, 138.7, 138.1, 129.6, 129.2, 121.1, 118.1, 118.0, 115.8, 114.8, 113.7, 55.2.

3.7.33. 6-Bromo-3-(3-chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**8k**)

White powder; mp = 305–307 °C; R_f = 0.81; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.19 (1H, s, -SH), 8.01 (1H, dd, *J* = 8.67, 2.26 Hz, arom.), 7.95–7.98 (1H, m, arom.), 7.47–7.52 (3H, m, arom.), 7.38–7.41 (1H, d, *J* = 8.67 Hz, arom.), 7.28–7.30 (1H, dt, *J* = 6.69, 1.93, 1.93 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.7, 140.3, 138.7, 138.4, 138.2, 132.9, 130.6, 129.2, 128.3, 127.8, 118.1, 115.9.

3.7.34. 7-Chloro-2-mercapto-3-methylquinazolin-4(3*H*)-one (**9a**)

White powder; mp = 327–328 °C; R_f = 0.87; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.99 (1H, s, -SH), 7.96 (1H, d, *J* = 8.07 Hz, arom.), 7.40 (1H, d, *J* = 1.47 Hz, arom.), 7.37 (1H, dd, *J* = 8.44, 1.83 Hz, arom.), 3.64 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 158.9, 139.9, 139.7, 129.5, 124.6, 114.9, 114.2, 33.3.

3.7.35. 7-Chloro-3-ethyl-2-mercaptoquinazolin-4(3*H*)-one (**9b**)

White powder; mp = 265 °C; R_f = 0.91; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.91 (1H, s, -SH), 7.90–7.93 (1H, d, *J* = 8.67 Hz, arom.), 7.31–7.35 (2H, m, arom.), 4.38–4.44 (2H, q, *J* = 6.78 Hz, -CH2-), 1.19–1.23 (3H, t, *J* = 6.78 Hz, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.2, 158.3, 139.8, 139.7, 129.3, 124.6, 124.5, 114.9, 114.4, 41.3, 11.8.

3.7.36. 3-Allyl-7-chloro-2-mercaptoquinazolin-4(3*H*)-one (**9c**)

White powder; mp = 248–249 °C; R_f = 0.89; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.99 (1H, s, -SH), 7.92–7.94 (1H, d, *J* = 8.67 Hz, arom.), 7.33–7.38 (2H, m, arom.), 5.88–5.90 (1H, m, -CH=), 5.13–5.19 (2H, m, -CH$_2$-), 4.99–5.02 (2H, d, *J* = 4.90 Hz, =CH$_2$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.5, 158.3, 139.8, 129.6, 129.3, 117.0, 115.0, 114.3, 47.8.

3.7.37. 7-Chloro-2-mercapto-3-phenylquinazolin-4(3*H*)-one (**9d**)

White powder; mp = 313 °C (288–289 °C [51]); R_f = 0.84; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.08 (1H, s, -SH), 7.93–7.96 (1H, d, *J* = 8.67 Hz, arom.), 7.36–7.51 (5H, m, arom.), 7.27–7.29 (2H, m,arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.5, 158.3, 140.4, 139.9, 139.0, 129.6, 128.9, 128.2, 124.4, 115.2, 114.9.

3.7.38. 3-Benzyl-7-chloro-2-mercaptoquinazolin-4(3*H*)-one (**9e**)

White powder; mp = 270–272 °C (255–257 °C [51]); R_f = 0.90; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.09 (1H, s, -SH), 7.93–7.96 (1H, d, *J* = 8.29 Hz, arom.), 7.23–7.42 (7H, m, arom.), 5.63 (2H, s, -CH$_2$-). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 158.3, 136.3, 129.5, 128.3, 128.2, 127.2, 127.1, 124.6, 115.0, 114.3, 48.7.

3.7.39. 7-Chloro-2-mercapto-3-(*p*-tolyl)quinazolin-4(3*H*)-one (**9f**)

White powder; mp = 307–309 °C (278–280 °C [51]); R_f = 0.87; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.05 (1H, s, -SH), 7.92–7.95 (1H, d, *J* = 8.67 Hz, arom.), 7.45 (1H, d, *J* = 1.88 Hz, arom.), 7.35–7.38 (1H, dd, *J* = 8.29, 1.88 Hz, arom.), 7.26–7.29 (2H, d, *J* = 8.29 Hz, arom.), 7.13–7.15 (2H, d, *J* = 8.29 Hz, arom.), 2.37 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.6, 158.3, 140.4, 139.8, 137.5, 136.5, 129.8, 129.6, 128.5, 124.3, 115.1, 114.9, 20.8.

3.7.40. 7-Chloro-3-(4-fluorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**9g**)

White powder; mp = 314–315 °C; R_f = 0.86; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.09 (1H, s, -SH), 7.93–7.95 (1H, d, *J* = 8.67 Hz, arom.), 7.55 (2H, d, *J* = 8.67 Hz, arom.), 7.46 (1H, d, *J* = 1.51 Hz, arom.), 7.33–7.37 (3H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.6, 163.2, 159.9, 159.2, 140.3, 139.9, 135.2, 131.5, 130.8, 129.6, 129.4, 124.4, 116.1, 115.9, 114.9, 114.7.

3.7.41. 7-Chloro-3-(4-chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**9h**)

White powder; mp = 302–303 °C (296 °C [53]); R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.12 (1H, s, -SH), 7.93–7.96 (1H, d, *J* = 8.67 Hz, arom.), 7.67–7.69 (2H, d, *J* = 8.67 Hz, arom.), 7.45 (1H, d, *J* = 1.51 Hz, arom.), 7.33–7.39 (3H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.4, 159.1, 140.4, 137.9, 132.9, 130.9, 129.0, 124.4, 115.0.

3.7.42. 3-(4-Bromophenyl)-7-chloro-2-mercaptoquinazolin-4(3*H*)-one (**9i**)

White powder; mp = 320–322 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.12 (1H, s, -SH), 7.93–7.96 (1H, d, *J* = 8.67 Hz, arom.), 7.67–7.70 (2H, d, *J* = 8.67 Hz, arom.), 7.46 (1H, d, *J* = 1.51 Hz, arom.), 7.36–7.39 (1H, dd, *J* = 8.67, 1.88 Hz, arom.), 7.26–7.29 (2H, d,

J = 8.67 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.3, 159.1, 140.4, 139.9, 138.4, 131.9, 131.3, 129.6, 124.4, 121.4, 115.2, 114.9.

3.7.43. 7-Chloro-2-mercapto-3-(3-methoxyphenyl)quinazolin-4(3*H*)-one (**9j**)

White powder; mp = 256–257 °C; R_f = 0.87; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.06 (1H, s, -SH), 7.93–7.96 (1H, d, J = 8.67 Hz, arom.), 7.46 (1H, d, J = 1.88 Hz, arom.), 7.35–7.38 (2H, m, arom.), 6.99 (1H, dd, J = 8.29, 1.88 Hz, arom.), 6.90–6.92 (1H, t, J = 2.07, 2.07 Hz, arom.), 6.84–6.86 (2H, m, arom.), 3.75 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.4, 159.8, 159.0, 140.4, 140.0, 139.9, 129.6, 124.3, 121.1, 115.2, 115.0, 114.9, 113.6, 55.0.

3.7.44. 7-Chloro-3-(3-chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**9k**)

White powder; mp = 248–249 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 13.13 (1H, s, -SH), 7.93–7.96 (1H, d, J = 8.67 Hz, arom.), 7.46–7.52 (5H, m, arom.), 7.37–7.40 (1H, d, arom.), 7.29–7.31 (1H, dd, J = 8.29, 1.88 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.3, 159.1, 140.4, 139.9, 132.9, 130.5, 129.6, 129.1, 128.3, 128.0, 127.8, 124.4, 115.2, 115.1, 99.5.

3.7.45. 6,8-Dichloro-2-mercapto-3-methylquinazolin-4(3*H*)-one (**10a**)

Pale yellow powder; mp = 246 °C; R_f = 0.91; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.86 (1H, s, -SH), 8.07 (1H, d, J = 2.93 Hz, arom.), 7.90 (1H, d, J = 2.93 Hz, arom.), 3.65 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.8, 157.9, 135.0, 134.6, 128.1, 125.6, 119.9, 118.2, 33.8.

3.7.46. 6,8-Dichloro-3-ethyl-2-mercaptoquinazolin-4(3*H*)-one (**10b**)

White needles; mp = 184 °C; R_f = 0.89; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.75 (1H, s, -SH), 8.05 (1H, d, J = 2.26 Hz, arom.), 7.88 (1H, d, J = 2.26 Hz, arom.), 4.43–4.45 (2H, q, J = 6.78 Hz, -CH2-), 1.21–1.25 (3H, t, J = 6.97 Hz, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.2, 157.3, 134.9, 134.7, 128.2, 125.6, 125.4, 119.8, 118.4, 41.8, 11.6.

3.7.47. 3-Allyl-6,8-dichloro-2-mercaptoquinazolin-4(3*H*)-one (**10c**)

White powder; mp = 179 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.84 (1H, s, -SH), 8.06 (1H, d, J = 2.20 Hz, arom.), 7.89 (1H, d, J = 2.93 Hz, arom.), 5.86–5.92 (1H, ddt, J = 16.96, 10.36, 5.41 Hz, -CH=), 5.17–5.20 (2H, m, -CH$_2$-), 5.03 (2H, m, =CH$_2$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.4, 157.3, 135.1, 134.8, 131.2, 128.2, 125.6, 119.9, 118.2, 117.3, 48.1.

3.7.48. 6,8-Dichloro-2-mercapto-3-phenylquinazolin-4(3*H*)-one (**10d**)

White powder; mp = 283–285 °C; R_f = 0.89; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.98 (1H, s, -SH), 8.11 (1H, d, J = 2.26 Hz, arom.), 7.89 (1H, d, J = 2.26 Hz, arom.), 7.42–7.52 (3H, m, arom.), 7.27–7.29 (2H, d, J = 7.16 Hz, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.6, 158.1, 139.1, 135.6, 134.8, 129.0, 128.7, 125.7, 119.9.

3.7.49. 3-Benzyl-6,8-dichloro-2-mercaptoquinazolin-4(3*H*)-one (**10e**)

White powder; mp = 206–208 °C; R_f = 0.93; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.94 (1H, s, -SH), 8.07 (1H, d, J = 2.26 Hz, arom.), 7.89 (1H, m, arom.), 7.23–7.34 (5H, m, arom.), 5.67 (2H, s, J = 7.16 Hz, -CH$_2$-). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 175.9, 157.8, 135.9, 134.9, 128.3, 127.1, 125.7, 120.0, 118.3, 49.2.

3.7.50. 6,8-Dichloro-2-mercapto-3-(*p*-tolyl)quinazolin-4(3*H*)-one (**10f**)

White powder; mp = 244 °C; R_f = 0.81; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.93 (1H, s, -SH), 8.10 (1H, d, J = 2.26 Hz, arom.), 7.87 (1H, d, J = 2.64 Hz, arom.), 7.27–7.30 (2H, d, J = 8.29 Hz, arom.), 7.13–7.16 (2H, d, J = 8.29 Hz, -CH$_2$-), 2.37 (3H, s, -CH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.7, 158.1, 137.6, 136.5, 135.5, 134.8, 129.6, 128.4, 128.1, 125.7, 119.9, 119.3, 20.8.

3.7.51. 6,8-Dichloro-3-(4-fluorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**10g**)

White powder; mp = 268–269 °C; R_f = 0.88; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.04 (1H, s, -SH), 8.11 (1H, d, *J* = 2.26 Hz, arom.), 7.88 (1H, d, *J* = 2.26 Hz, arom.), 7.33–7.35 (4H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.7, 163.2, 160.0, 158.2, 135.5, 134.9, 130.9, 128.1, 125.7, 119.9, 119.3, 116.1, 115.8.

3.7.52. 6,8-Dichloro-3-(4-chlorophenyl)-2-mercaptoquinazolin-4(3*H*)-one (**10h**)

White powder; mp = 259–260 °C; R_f = 0.89; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.07 (1H, s, -SH), 8.11 (1H, d, *J* = 2.93 Hz, arom.), 7.88 (1H, d, *J* = 2.20 Hz, arom.), 7.56 (2H, m, arom.), 7.33–7.34 (2H, m, arom.). ^{13}C NMR (CDCl3, 75 MHz) δ 176.5, 158.0, 138.0, 135.6, 134.9, 132.9, 130.8, 129.1, 128.9, 125.7, 119.9, 119.3.

3.7.53. 3-(4-Bromophenyl)-6,8-dichloro-2-mercaptoquinazolin-4(3H)-one (**10i**)

White powder; mp = 280–282 °C; R_f = 0.80; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 12.07 (1H, s, -SH), 8.11 (1H, d, *J* = 2.20 Hz, arom.), 7.88 (1H, d, *J* = 2.20 Hz, arom.), 7.68–7.70 (2H, m, arom.), 7.26–7.28 (2H, m, arom.). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.4, 158.0, 138.5, 135.5, 134.9, 132.1, 131.9, 131.2, 131.1, 128.1, 125.7, 121.5, 119.9, 119.3.

3.7.54. 6,8-Dichloro-2-mercapto-3-(3-methoxyphenyl)quinazolin-4(3H)-one (**10j**)

White powder; mp = 219–220 °C; R_f = 0.85; ^{1}H NMR (DMSO-d_6, 300 MHz) δ 11.97 (1H, s, -SH), 8.11 (1H, d, *J* = 2.26 Hz, arom.), 7.88 (1H, d, *J* = 2.26 Hz, arom.), 7.39 (1H, m, arom.), 6.91 (1H, m, arom.), 6.87 (2H, m, arom.), 3.76 (3H, s, -OCH$_3$). ^{13}C NMR (CDCl$_3$, 75 MHz) δ 176.4, 159.8, 157.9, 140.1, 135.5, 134.9, 129.7, 125.7, 121.0, 120.9, 119.3, 114.3, 113.8, 55.2.

4. Conclusions

DESs were found to be good solvents for catalyst-free synthesis of 2-mercaptoquinazolin-4(3*H*)-ones. Twenty different DESs were screened for their ability to serve as a solvent in the reaction of anthranilic acid and isothicyanates and the most effective solvent was proven to be choline chloride:urea (1:2). DESs were combined with microwave-promoted synthesis and ultrasound promoted synthesis, but the best method was found to be a simple stirring at 80 °C. Fifty-five different 2-mercaptoquinazolin-4(3*H*)-ones were synthesized using this simple method. The importance of using these methods towards conventional ones is manifested in a shorter reaction time, simplicity of operation, no use of catalysts and no need for product purification.

References

1. Asif, M. Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives. *Int. J. Med. Chem.* **2014**, *2014*, 395637. [CrossRef] [PubMed]
2. Sayyed, M.A.; Mokle, S.S.; Vibhute, Y.B. Synthesis of 6-Iodo / Bromo- 3-Amino-2-Methylquinazolin-4 (3*H*)-Ones by Direct Halogenation and Their Schiff Base Derivatives. *ARKIVOC* **2006**, *2006*, 221–226. [CrossRef]
3. Mohamed, M.A.; Ayyad, R.R.; Shawer, T.Z.; Abdel-Aziz, A.A.-M.; El-Azab, A.S. Synthesis and Antitumor Evaluation of Trimethoxyanilides Based on 4(3*H*)-Quinazolinone Scaffolds. *Eur. J. Med. Chem.* **2016**, *112*, 106–113. [CrossRef]
4. El-Azab, A.S.; Eltahir, K.E.H. Design and Synthesis of Novel 7-Aminoquinazoline Derivatives: Antitumor and Anticonvulsant Activities. *Bioorg. Med. Chem. Lett.* **2012**, *22*, 1879–1885. [CrossRef] [PubMed]
5. Sakr, A.; Rezq, S.; Ibrahim, S.M.; Soliman, E.; Baraka, M.M.; Romero, D.G.; Kothayer, H. Design and Synthesis of Novel Quinazolinones Conjugated Ibuprofen, Indole Acetamide, or Thioacetohydrazide as Selective COX-2 Inhibitors: Anti-Inflammatory, Analgesic and Anticancer Activities. *J. Enzym. Inhib. Med. Chem.* **2021**, *36*, 1810–1828. [CrossRef]
6. El-Subbagh, H.I.; Sabry, M.A. 2-Substituted-Mercapto-Quinazolin-4(3H)-Ones as DHFR Inhibitors. *Mini Rev. Med. Chem.* **2021**, *21*, 2249–2260. [CrossRef]
7. El-Azab, A.S.; Abdel-Aziz, A.A.-M.; Bua, S.; Nocentini, A.; AlSaif, N.A.; Alanazi, M.M.; El-Gendy, M.A.; Ahmed, H.E.A.; Supuran, C.T. S-Substituted 2-Mercaptoquinazolin-4(3H)-One and 4-Ethylbenzensulfonamides Act as Potent and Selective Human Carbonic Anhydrase IX and XII Inhibitors. *J. Enzym. Inhib. Med. Chem.* **2020**, *35*, 733–743. [CrossRef]
8. Hour, M.J.; Huang, L.J.; Kuo, S.C.; Xia, Y.; Bastow, K.; Nakanishi, Y.; Hamel, E.; Lee, K.H. 6-Alkylamino- and 2,3-Dihydro-3′-Methoxy-2-Phenyl-4-Quinazolinones and Related Compounds: Their Synthesis, Cytotoxicity, and Inhibition of Tubulin Polymerization. *J. Med. Chem.* **2000**, *43*, 4479–4487. [CrossRef] [PubMed]
9. Nerkar, A.; Saxena, A.; Ghone, S.; Thaker, A. In Silico Screening, Synthesis and In Vitro Evaluation of Some Quinazolinone and Pyridine Derivatives as Dihydrofolate Reductase Inhibitors for Anticancer Activity. *Eur.-J. Chem.* **2009**, *6*, S97–S102. [CrossRef]
10. Cheng, C.; Yun, F.; He, J.; Ullah, S.; Yuan, Q. Design, Synthesis and Biological Evaluation of Novel Thioquinazolinone-Based 2-Aminobenzamide Derivatives as Potent Histone Deacetylase (HDAC) Inhibitors. *Eur. J. Med. Chem.* **2019**, *173*, 185–202. [CrossRef]
11. Moussa, G.; Alaaeddine, R.; Alaeddine, L.M.; Nassra, R.; Belal, A.S.F.; Ismail, A.; El-Yazbi, A.F.; Abdel-Ghany, Y.S.; Hazzaa, A. Novel Click Modifiable Thioquinazolinones as Anti-Inflammatory Agents: Design, Synthesis, Biological Evaluation and Docking Study. *Eur. J. Med. Chem.* **2018**, *144*, 635–650. [CrossRef] [PubMed]
12. Auti, P.S.; George, G.; Paul, A.T. Recent Advances in the Pharmacological Diversification of Quinazoline/Quinazolinone Hybrids. *RSC Adv.* **2020**, *10*, 41353–41392. [CrossRef]
13. Kumar Tiwary, B.; Pradhan, K.; Kumar Nanda, A.; Chakraborty, R. Implication of Quinazoline-4(3*H*)-Ones in Medicinal Chemistry: A Brief Review. *J. Chem. Biol. Ther.* **2015**, *1*, 104. [CrossRef]
14. Converso, A.; Hartingh, T.; Garbaccio, R.M.; Tasber, E.; Rickert, K.; Fraley, M.E.; Yan, Y.; Kreatsoulas, C.; Stirdivant, S.; Drakas, B.; et al. Development of Thioquinazolinones, Allosteric Chk1 Kinase Inhibitors. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 1240–1244. [CrossRef]
15. Cao, S.-L.; Zhang, M.; Feng, Y.-P.; Jiang, Y.-Y.; Zhang, N. Synthesis of 3-Aryl-4(3*H*)-Quinazolinones from Anthranilic Acids and Triethyl Orthoformate. *Synth. Comm.* **2008**, *38*, 2227–2236. [CrossRef]
16. Baghbanzadeh, M.; Molnar, M.; Damm, M.; Reidlinger, C.; Dabiri, M.; Kappe, C.O. Parallel Microwave Synthesis of 2-Styrylquinazolin-4(3H)-Ones in a High-Throughput Platform Using HPLC/GC Vials as Reaction Vessels. *J. Comb. Chem.* **2009**, *11*, 676–684. [CrossRef] [PubMed]
17. Komar, M.; Molnar, M.; Konjarević, A. Screening of Natural Deep Eutectic Solvents for Green Synthesis of 2-Methyl-3-Substituted Quinazolinones and Microwave-Assisted Synthesis of 3-Aryl Quinazolinones in Ethanol. *Croat. Chem. Acta* **2019**, *92*, 511–517. [CrossRef]
18. Purkhosrow, A.; Khalili, A.; Chih Ho, A.; Mowlazadeh Haghighi, S.; Fakher, S.; Khalafi-Nezhad, A. Highly Efficient, One Pot, Solvent and Catalyst, Free Synthesis of Novel Quinazoline Derivatives under Ultrasonic Irradiation and Their Vasorelaxant Activity Isolated Thoracic Aorta of Rat. *Iran. J. Pharm. Res.* **2019**, *18*, 607–619. [CrossRef]
19. Adib, M.; Ansari, S.; Mohammadi, A.; Bijanzadeh, H. A Novel, One-Pot, Solvent-, and Catalyst-Free Synthesis of 2-Aryl/Alkyl-4(3H)-Quinazolinones. *Tetrahedron Lett.* **2010**, *51*, 30–32. [CrossRef]
20. Abbas, S.; Barsoum, F.; Georgey, H.; Raafat, E. Synthesis and Antitumor Activity of Certain 2,3,6-Trisubstituted Quinazolin-4(3H)-One Derivatives. *Bull. Fac. Pharm. Cairo Univ.* **2013**, *51*, 273–282. [CrossRef]
21. Ma, Y.; Ren, D.; Zhang, J.; Liu, J.; Zhao, J.; Wang, L.; Zhang, F. Synthesis, Antibacterial Activities Evaluation, and Docking Studies of Some 2-Substituted-3-(Phenylamino)-Dihydroquinazolin-4(1*H*)-Ones. *Tetrahedron Lett.* **2015**, *56*, 4076–4079. [CrossRef]
22. Zhang, J.; Ren, D.; Ma, Y.; Wang, W.; Wu, H. CuO Nanoparticles Catalyzed Simple and Efficient Synthesis of 2,3-Dihydroquinazolin-4(1*H*)-Ones and Quinazolin-4(3*H*)-Ones under Ultrasound Irradiation in Aqueous Ethanol under Ultrasound Irradiation in Aqueous Ethanol. *Tetrahedron* **2014**, *70*, 5274–5282. [CrossRef]
23. Lobo, H.R.; Singh, B.S.; Shankarling, G.S. Bio-Compatible Eutectic Mixture for Multi-Component Synthesis: A Valuable Acidic Catalyst for Synthesis of Novel 2,3-Dihydroquinazolin-4(1H)-One Derivatives. *Catal. Commun.* **2012**, *27*, 179–183. [CrossRef]
24. Jagani, C.; Sojitra, N.; Vanparia, S.; Patel, T.; Dixit, R.; Dixit, B. Microwave Promoted Synthesis and Antimicrobial Activity of 3-Thiazole Substituted 2-Styryl-4(3*H*)-Quinazolinone Derivatives. *J. Saudi Chem. Soc.* **2012**, *16*, 363–369. [CrossRef]

25. Komar, M.; Molnar, M.; Jukić, M.; Glavaš-Obrovac, L.; Opačak-Bernardi, T. Green Chemistry Approach to the Synthesis of 3-Substituted-Quinazolin-4(3*H*)-Ones and 2-Methyl-3-Substituted-Quinazolin-4(3*H*)-Ones and Biological Evaluation. *Green Chem. Lett. Rev.* **2020**, *13*, 93–101. [CrossRef]

26. Li, X.; Lin, Q.; Wang, L. One-Pot Solvent-Free Synthesis of 2,3-Disubstituted 4(3*H*)-Quinazolinones Catalyzed by Long-Chain Double SO$_3$H-Functionalized Brønsted Acidic Ionic Liquids under Microwave Irradiation. *J. Iran. Chem. Soc.* **2015**, *12*, 897–901. [CrossRef]

27. Arafa, W. Deep Eutectic Solvent for an Expeditious Sono-Synthesis of Novel Series of Bis-Quinazolin- 4-One Derivatives as Potential Anti-Cancer Agents. *R. Soc. Open Sci.* **2019**, *6*, 182046. [CrossRef] [PubMed]

28. Larksarp, C.; Alper, H. Palladium-Catalyzed Cyclocarbonylation of *o*-Iodoanilines with Heterocumulenes: Regioselective Preparation of 4(3*H*)-Quinazolinone Derivatives. *J. Org. Chem.* **2000**, *65*, 2773–2777. [CrossRef]

29. El-Azab, A.S. Synthesis of Some New Substituted 2-Mercaptoquinazoline Analogs as Potential Antimicrobial Agents. *Phosphorus Sulfur Silicon Relat. Elem.* **2007**, *182*, 333–348. [CrossRef]

30. Alafeefy, A. Some New Quinazolin-4(3*H*)-One Derivatives, Synthesis and Antitumor Activity. *J. Saudi Chem. Soc.* **2011**, *15*, 337–343. [CrossRef]

31. Al-Khuzaie, M.; Al-Majidi, S. Synthesis, Characterization and Evaluation Antimicrobial Activity of Some New Substituted 2-Mercapto-3-Phenyl-4(3H)-Quinazolinone. *Iraqi J. Sci.* **2014**, *55*, 582–593.

32. Ramadan, S.K.; Elrazaz, E.Z.; Abouzid, K.A.M.; El-Naggar, A.M. Design, Synthesis and *in Silico* Studies of New Quinazolinone Derivatives as Antitumor PARP-1 Inhibitors. *RSC Adv.* **2020**, *10*, 29475–29492. [CrossRef]

33. Molnar, M.; Klenkar, J.; Tarnai, T. Eco-Friendly Rapid Synthesis of 3-Substituted-2-Thioxo-2,3-Dihydroquinazolin-4(1*H*)-Ones in Choline Chloride Based Deep Eutectic Solvent. *Synt. Commun.* **2017**, *47*, 1040–1045. [CrossRef]

34. Ghosh, S.K.; Nagarajan, R. Deep Eutectic Solvent Mediated Synthesis of Quinazolinones and Dihydroquinazolinones: Synthesis of Natural Products and Drugs. *RSC Adv.* **2016**, *6*, 27378–27387. [CrossRef]

35. Abbott, A.P.; Capper, G.; Davies, D.L.; Rasheed, R.K.; Tambyrajah, V. Novel Solvent Properties of Choline Chloride/Urea Mixtures. *Chem. Commun.* **2003**, *2003*, 70–71. [CrossRef]

36. Hansen, B.B.; Spittle, S.; Chen, B.; Poe, D.; Zhang, Y.; Klein, J.M.; Horton, A.; Adhikari, L.; Zelkovich, T.; Doherty, B.W.; et al. Deep Eutectic Solvents: A Review of Fundamentals and Applications. *Chem. Rew.* **2020**, *121*, 1232–1285. [CrossRef]

37. Alonso, D.A.; Baeza, A.; Chinchilla, R.; Guillena, G.; Pastor, I.M.; Ramón, D.J. Deep Eutectic Solvents: The Organic Reaction Medium of the Century. *Eur. J. Org. Chem.* **2016**, *2016*, 612–632. [CrossRef]

38. Inaloo, I.D.; Majnooni, S. Carbon Dioxide Utilization in the Efficient Synthesis of Carbamates by Deep Eutectic Solvents (DES) as Green and Attractive Solvent/Catalyst Systems. *New J. Chem.* **2019**, *43*, 11275–11281. [CrossRef]

39. Dindarloo Inaloo, I.; Majnooni, S. Ureas as Safe Carbonyl Sources for the Synthesis of Carbamates with Deep Eutectic Solvents (DESs) as Efficient and Recyclable Solvent/Catalyst Systems. *New J. Chem.* **2018**, *42*, 13249–13255. [CrossRef]

40. Wazeer, I.; Hayyan, M.; Hadj-Kali, M. Deep Eutectic Solvents: Designer Fluids for Chemical Processes. *J. Chem. Technol. Biotechnol.* **2018**, *93*, 945–958. [CrossRef]

41. Kappe, C.O. Controlled Microwave Heating in Modern Organic Synthesis. *Angew. Chem. Int. Ed.* **2004**, *43*, 6250–6284. [CrossRef] [PubMed]

42. Liu, Y.; Myers, E.J.; Rydahl, S.A.; Wang, X. Ultrasonic-Assisted Synthesis, Characterization, and Application of a Metal–Organic Framework: A Green General Chemistry Laboratory Project. *J. Chem. Educ.* **2019**, *96*, 2286–2291. [CrossRef]

43. Molnar, M.; Periš, I.; Komar, M. Choline Chloride Based Deep Eutectic Solvents as a Tuneable Medium for Synthesis of Coumarinyl 1,2,4-Triazoles: Effect of Solvent Type and Temperature. *Eur. J. Org. Chem.* **2019**, *2019*, 2688–2694. [CrossRef]

44. Molnar, M.; Jakovljević, M.; Jokić, S. Optimization of the Process Conditions for the Extraction of Rutin from *Ruta graveolens* L. by Choline Chloride Based Deep Eutectic Solvents. *Solvent Extr. Res. Dev. Jpn.* **2018**, *25*, 109–116. [CrossRef]

45. Cunha, S.C.; Fernandes, J.O. Extraction Techniques with Deep Eutectic Solvents. *Trends Anal. Chem.* **2018**, *105*, 225–239. [CrossRef]

46. Dai, Y.; Van Spronsen, J.; Witkamp, G.-J.; Verpoorte, R.; Choi, Y.H. Natural Deep Eutectic Solvents as New Potential Media for Green Technology. *Anal. Chim. Acta* **2013**, *766*, 61–68. [CrossRef] [PubMed]

47. Mjalli, F.S.; Ahmed, O.U. Characteristics and Intermolecular Interaction of Eutectic Binary Mixtures: Reline and Glyceline. *Korean J. Chem. Eng.* **2016**, *33*, 337–343. [CrossRef]

48. Castro, A.; Jerez, M.J.; Gil, C.; Calderón, F.; Doménech, T.; Nueda, A.; Martínez, A. CODES, a Novel Procedure for Ligand-Based Virtual Screening: PDE7 Inhibitors as an Application Example. *Eur. J. Med. Chem.* **2008**, *43*, 1349–1359. [CrossRef]

49. El-Sharief, A.; Ammar, Y.; Mohamed, Y.; El-Gaby, M. A Comparative Study of the Behavior of Cyanothioformamide and Oxazolidine (Thiones or Iminothiones) Towards Some Binucleophiles. *Heteroat. Chem.* **2002**, *13*, 291–298. [CrossRef]

50. Yavari, I.; Beheshti, S. Reaction of Primary Alkylamines, Heterocumulenes, and Isatoic Anhydride, Catalyzed by Magnetic Fe3O4 Nanoparticles in H2O. *Helv. Chim. Acta* **2011**, *94*, 1825–1830. [CrossRef]

51. Dou, G.; Wang, M.; Shi, D. One-Pot Synthesis of Quinazolinone Derivatives from Nitro-Compounds with the Aid of Low-Valent Titanium. *J. Comb. Chem.* **2009**, *11*, 151–154. [CrossRef] [PubMed]

52. Lakhan, R.; Srivastava, M. A Convenient Preparation of 2-Thioxo-4(3H)-Quinazolinones. *Proc. Indian Acad. Sci. (Chem. Sci.)* **1993**, *105*, 11–17. [CrossRef]

53. Wang, M.; Dou, G.; Shi, D.-Q. One-pot Synthesis of 2,3-dihydro-2-thioxoquinazolin-4(1H)-ones from Nitro-compounds with the Aid of Tin(II) Chloride. *J. Heterocycl. Chem.* **2010**, *47*, 939–943. [CrossRef]

54.   Liu, W.; Zhang, Q.; Gong, F.; Cao, Z.; Huo, Y. A Convenient and Efficient Synthesis of 2-Thioxoquinazolinone Derivatives via Microwave Irradiation. *J. Heterocycl. Chem.* **2014**, *52*, 317–321. [CrossRef]
55.   El-Gaby, M.S.A.; Ammar, Y.A.; El-Sharief, A.M.S.; Zahran, M.A.; Khames, A.A. Reactivity of Cyanothioformamides and 3-(4-Bromophenyl)-5-Imino-4-Oxazolidinethione toward Ortho-Substituted Nucleophiles. *Heteroat. Chem.* **2002**, *13*, 611–616. [CrossRef]
56.   Al Alshaikh, M.; Danah, A.-S.; Fatima, E.-B. Synthesis of Some-2-Thioxo-3-Substituted-2,3-Dihydro-1H-Quinazolin-4-One Derivatives as Potential Antibacterial and Antifungal Agents. *Res. J. Chem. Environ.* **2013**, *17*, 48–52.
57.   Mayoral, J.; Melendez, E.; Merchán, F.; Sanchez, J. Preparation of 3-Aryl-4-Oxo-2-Thioxo-1,2,3,4-Tetrahydroquinazolines from Methyl *N*-Aryldithiocarbamates and Anthranilic Acid. *Synthesis* **1981**, *1981*, 962. [CrossRef]